Researcher
- m.zietse@erasmusmc.nl
Erasmus School of Health Policy & Management
External PhD candidate | Health Technology Assessment (HTA)
- zietse@eshpm.eur.nl
More information
Work
- Michiel Zietse, Jaimy R.D. Raijmaakers, Aart Beeker, Leontine E.A.M.M. Spierings, Thijs J. Giezen, Agnes Jager, Tim Kanters, Birgit Koch, Ron Mathijssen, Frederick Thielen & Roelof van Leeuwen (2026) - Optimizing Cancer Care Delivery: Capacity and Cost Benefits of Home-Based Self-Administration of Subcutaneous Trastuzumab - JCO Oncology Practice - doi: 10.1200/OP-26-00660
- Michiel Zietse, Jacky Hu, Esther R. van Staveren, Leontine E.A.M.M. Spierings, Agnes Jager, Birgit C.P. Koch, Ron H.J. Mathijssen, Roelof W.F. van Leeuwen & Frederick W. Thielen (2025) - Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study - Breast, 84 - doi: 10.1016/j.breast.2025.104573 - [link]
- Michiel Zietse, Thirza Kooijman, Ruben Malmberg, Leontine E A M M Spierings, Agnes Jager, Ron H J Mathijssen, Roelof W F van Leeuwen & Frederick W Thielen (2025) - Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis - JCO Oncology Practice, 21 (9), 1287 - 1295 - doi: 10.1200/OP-24-00804 - [link]
- Michiel Zietse, Luuk C Aalders, Leontine E A M M Spierings, Nikki De Rouw, Wouter Dercksen, Virgil A S H Dalm, Esther Oomen-de Hoop, Frederick W Thielen, Birgit C P Koch, Ron H J Mathijssen, Leni van Doorn & Roelof W F van Leeuwen (2025) - Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial - BMJ open, 15 (4), e102770 - doi: 10.1136/bmjopen-2025-102770 - [link]
- Michiel Zietse, Shannon L. van der Zeeuw, Anne Sophie Klein Gebbink, Annemarie C. de Vries, Marie Rose B.S. Crombag, Roelof W.F. van Leeuwen & Maaike J. Hoedemakers (2025) - Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach - Applied Health Economics and Health Policy, 23 (2), 183-195 - doi: 10.1007/s40258-024-00937-6 - [link]
- Michiel Zietse, Roelof W.F. van Leeuwen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Jolanda E. de Boer, Rudy Dupree, Ron H.J. Mathijssen & Lonneke Timmers (2024) - Interchangeability of immune checkpoint inhibitors: an urgent need for action - The Lancet Oncology, 25 (11), e611-e616 - doi: 10.1016/S1470-2045(24)00212-2 - [link]
- Michiel Zietse, Ruben Malmberg, Roelof W.F. van Leeuwen, Frederick W. Thielen & Carin A. Uyl – de Groot (2024) - The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective - Bmc Health Services Research, 24 (1) - doi: 10.1186/s12913-024-11719-0 - [link]
- Ruben Malmberg, Leni van Doorn, Juul M. Cox, Alaa Daloul, Halima Ettafahi, Esther Oomen-De Hoop, Michiel Zietse, Monique E.M.M. Bos, Birgit C.P. Koch & Roelof W.F. van Leeuwen (2024) - Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study - JCO Oncology Practice, 20 (9), 1243-1251 - doi: 10.1200/OP.24.00110 - [link]
- Ruben Malmberg, Michiel Zietse, Daphne W. Dumoulin, Jeroen J.M.A. Hendrikx, Joachim G.J.V. Aerts, Astrid A.M. van der Veldt, Birgit C.P. Koch, Stefan Sleijfer & Roelof W.F. van Leeuwen (2022) - Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab - The Lancet Oncology, 23 (12), e552-e561 - doi: 10.1016/S1470-2045(22)00554-X - [link]
